242 related articles for article (PubMed ID: 28763340)
1. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis.
Kamal F; Khan MA; Khan Z; Cholankeril G; Hammad TA; Lee WM; Ahmed A; Waters B; Howden CW; Nair S; Satapathy SK
Eur J Gastroenterol Hepatol; 2017 Oct; 29(10):1109-1117. PubMed ID: 28763340
[TBL] [Abstract][Full Text] [Related]
2. Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.
Goel A; Rahim U; Nguyen LH; Stave C; Nguyen MH
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1029-1036. PubMed ID: 28994123
[TBL] [Abstract][Full Text] [Related]
3. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis.
Menshawy A; Mattar O; Barssoum K; AboEl-Naga AM; Salim HM; Mohamed AMF; Elgebaly A; Abd-Elsalam S
Curr Drug Targets; 2019; 20(4):380-387. PubMed ID: 30246636
[TBL] [Abstract][Full Text] [Related]
5. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
Lutz P; Parcina M; Bekeredjian-Ding I; Nischalke HD; Nattermann J; Sauerbruch T; Hoerauf A; Strassburg CP; Spengler U
PLoS One; 2014; 9(4):e93909. PubMed ID: 24714550
[TBL] [Abstract][Full Text] [Related]
6. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.
Hanouneh MA; Hanouneh IA; Hashash JG; Law R; Esfeh JM; Lopez R; Hazratjee N; Smith T; Zein NN
J Clin Gastroenterol; 2012 Sep; 46(8):709-15. PubMed ID: 22878533
[TBL] [Abstract][Full Text] [Related]
7. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome.
Ibrahim ES; Alsebaey A; Zaghla H; Moawad Abdelmageed S; Gameel K; Abdelsameea E
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1247-1250. PubMed ID: 28902040
[TBL] [Abstract][Full Text] [Related]
8. Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention.
Oliver A; Wong M; Sanchez C
South Med J; 2018 Nov; 111(11):660-665. PubMed ID: 30392000
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Mostafa T; Badra G; Abdallah M
Turk J Gastroenterol; 2015 Mar; 26(2):163-9. PubMed ID: 25835116
[TBL] [Abstract][Full Text] [Related]
10. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.
Soni H; Kumar-M P; Sharma V; Bellam BL; Mishra S; Mahendru D; Mandavdhare HS; Medhi B; Dutta U; Singh V
Hepatol Int; 2020 May; 14(3):399-413. PubMed ID: 32266675
[TBL] [Abstract][Full Text] [Related]
11. The role of rifaximine in the prevention of the spontaneous bacterial peritonitis.
Dănulescu RM; Ciobică A; Stanciu C; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):315-20. PubMed ID: 24340510
[TBL] [Abstract][Full Text] [Related]
12. Norfloxacin versus alternative antibiotics for prophylaxis of spontaneous bacteria peritonitis in cirrhosis: a systematic review and meta-analysis.
Song S; Yang Y; Geng C; Tang Z; Wang C; Li X
BMC Infect Dis; 2023 Aug; 23(1):557. PubMed ID: 37641014
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
Assem M; Elsabaawy M; Abdelrashed M; Elemam S; Khodeer S; Hamed W; Abdelaziz A; El-Azab G
Hepatol Int; 2016 Mar; 10(2):377-85. PubMed ID: 26660707
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.
Lutz P; Parcina M; Bekeredjian-Ding I; Hoerauf A; Strassburg CP; Spengler U
Infection; 2014 Feb; 42(1):175-7. PubMed ID: 23526308
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
[TBL] [Abstract][Full Text] [Related]
16. Norfloxacin, ciprofloxacin, trimethoprim-sulfamethoxazole, and rifaximin for the prevention of spontaneous bacterial peritonitis: a network meta-analysis.
Wang W; Yang J; Liu C; Song P; Wang W; Xu H; Xia X
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):905-910. PubMed ID: 31107737
[TBL] [Abstract][Full Text] [Related]
17. The Use of Rifaximin in Patients With Cirrhosis.
Caraceni P; Vargas V; Solà E; Alessandria C; de Wit K; Trebicka J; Angeli P; Mookerjee RP; Durand F; Pose E; Krag A; Bajaj JS; Beuers U; Ginès P;
Hepatology; 2021 Sep; 74(3):1660-1673. PubMed ID: 33421158
[TBL] [Abstract][Full Text] [Related]
18. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis.
Mandorfer M; Bota S; Schwabl P; Bucsics T; Pfisterer N; Kruzik M; Hagmann M; Blacky A; Ferlitsch A; Sieghart W; Trauner M; Peck-Radosavljevic M; Reiberger T
Gastroenterology; 2014 Jun; 146(7):1680-90.e1. PubMed ID: 24631577
[TBL] [Abstract][Full Text] [Related]
19. Primary and secondary prophylaxis of spontaneous bacterial peritonitis: current state of the art.
Facciorusso A; Antonino M; Orsitto E; Sacco R
Expert Rev Gastroenterol Hepatol; 2019 Aug; 13(8):751-759. PubMed ID: 31304804
[No Abstract] [Full Text] [Related]
20. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.
Vlachogiannakos J; Viazis N; Vasianopoulou P; Vafiadis I; Karamanolis DG; Ladas SD
J Gastroenterol Hepatol; 2013 Mar; 28(3):450-5. PubMed ID: 23216382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
